Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

David S. Hong, MD, on a Novel First-in-Class Agent Under Study in Non–Small Cell Lung Cancer

Posted: Tuesday, September 29, 2020

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses his study findings on sotorasib, a first-in-class oral KRASG12C inhibitor, and the clinical implications of treating already heavily pretreated patients with non–small cell lung cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.